The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study
Authors' conclusion
Diabetes status and elevated NT-proBNP were independently and jointly associated with MACCEs and all-cause mortality in patients with NSTE-ACS.
Study context
- Population
- Patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS), Beijing Friendship Hospital; nine groups by diabetes status and NT-proBNP tertiles (< 92, 92–335, ≥ 336 pg/ml)
- Participants
- 7,956 patients
- Exposure
- Joint categories of diabetes status and NT-proBNP tertiles
- Outcome
- MACCEs and all-cause mortality
Methodological detailssingle database (Cardiovascular Center Beijing Friendship Hospital Database Bank), multivariable Cox proportional hazards models
- Single database (Cardiovascular Center Beijing Friendship Hospital Database Bank)
- Multivariable Cox proportional hazards models
Main finding
As reported in the abstract
20,257.9 person-years of follow-up
Estimate (95% CI)
Diabetes + NT-proBNP ≥ 336 pg/mlvs Normoglycemia + NT-proBNP < 92 pg/ml
HR (MACCEs) 2.67(1.83–3.89)
Diabetes + NT-proBNP ≥ 336 pg/mlvs Normoglycemia + NT-proBNP < 92 pg/ml
HR (all-cause mortality) 2.98(1.48–6.00)
- Major adverse cardio-cerebral events (MACCEs) documented
- 1070
Observational data: associations, not effects.
Further findings
Independent association of diabetes with MACCEs and all-cause mortality (fully adjusted)
- Diabetes, MACCEs: HR
- 1.42 (1.20-1.68) (95% CI)
- Diabetes, all-cause mortality: HR
- 1.37 (1.05-1.78) (95% CI)
Independent association of higher NT-proBNP with MACCEs and all-cause mortality (fully adjusted)
- Higher NT-proBNP, MACCEs: HR
- 1.72 (1.40-2.11) (95% CI)
- Higher NT-proBNP, all-cause mortality: HR
- 2.80 (1.89-4.17) (95% CI)
Original publication
The joint association of diabetes status and NT-ProBNP with adverse cardiac outcomes in patients with non-ST-segment elevation acute coronary syndrome: a prospective cohort study. Cardiovasc Diabetol. Published 4 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →